What is Venture Philanthropy?

EBRP's Venture Philanthropy model leverages concepts from principal investing and applies them towards achieving philanthropic goals. When making a grant to a research project, we retain the added upside of generating a recurring donation stream if the therapy or product is commercially successful. That revenue then goes back into funding additional EB research, giving your donation the potential to grow to multiples of its original value.

FDA's Approval of Vyjuvek

Promotional graphic with pink background featuring two people celebrating, with text announcing FDA approval for a DEB treatment in the U.S., dated May 2023.

The FDA's approval of Vyjuvek, the first-ever approved EB treatment, marks a milestone in EBRP’s mission to discover treatments and a cure for EB. It provides validation for our scalable and sustainable Venture Philanthropy business model and most importantly creates hope for families around the world battling EB every day.
 
EBRP’s Venture Philanthropy business model has been highlighted for its leadership by Harvard Business School, Yale University, and MIT in helping to fast-track not only a cure for EB but therapies that could affect thousands of other rare diseases.

Learn More

Logo for Venture Into Cures featuring a DNA strand with purple butterflies and text.

To realize our vision of a world without EB, we're building a model based on three core pillars: Share, Collaborate, Cure. Learn more about our Venture Into Cures methodology to accelerate the path to EB therapies. Read more

Global Genes logo with slogan 'Allies in Rare Disease' featuring a stylized denim ribbon.

Global Genes covers our model from Venture Philanthopy, to strategic partnerships, and our vision for a first-of-its kind data platform to advance treatments and cures for EB in this case study. Read more.